Details for New Drug Application (NDA): 216783
✉ Email this page to a colleague
NDA 216783 describes CYCLOPHOSPHAMIDE, which is a drug marketed by Alembic, Ani Pharms, Cipla, Eirgen, Hikma, Senores Pharms, Zydus Lifesciences, Amneal, Baxter Hlthcare, Epic Pharma Llc, Hainan Poly, Hengrui Pharma, Sagent Pharms Inc, Sunny, Xgen Pharms, Baxter Hlthcare Corp, Dr Reddys, Eugia Pharma Speclts, Nexus, Sandoz, and Roxane, and is included in twenty-six NDAs. It is available from twenty-four suppliers. There are three patents protecting this drug. Additional details are available on the CYCLOPHOSPHAMIDE profile page.
The generic ingredient in CYCLOPHOSPHAMIDE is cyclophosphamide. There are nineteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.
The generic ingredient in CYCLOPHOSPHAMIDE is cyclophosphamide. There are nineteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.
Summary for 216783
| Tradename: | CYCLOPHOSPHAMIDE |
| Applicant: | Nexus |
| Ingredient: | cyclophosphamide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 216783
Suppliers and Packaging for NDA: 216783
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | cyclophosphamide | SOLUTION;INTRAVENOUS | 216783 | ANDA | Nexus Pharmaceuticals, LLC | 14789-125 | 14789-125-05 | 1 VIAL, GLASS in 1 CARTON (14789-125-05) / 2.5 mL in 1 VIAL, GLASS (14789-125-07) |
| CYCLOPHOSPHAMIDE | cyclophosphamide | SOLUTION;INTRAVENOUS | 216783 | ANDA | Nexus Pharmaceuticals, LLC | 14789-126 | 14789-126-05 | 1 VIAL, GLASS in 1 CARTON (14789-126-05) / 5 mL in 1 VIAL, GLASS (14789-126-07) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 500MG/2.5ML (200MG/ML) | ||||
| Approval Date: | Oct 29, 2024 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 1GM/5ML (200MG/ML) | ||||
| Approval Date: | Oct 29, 2024 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
